Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; chlorphenamine maleate, quantity: 2 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; pregelatinised maize starch; povidone; purified water; erythrosine aluminium lake; stearic acid - temporary relief of the symptoms of sinus headache, pain and nasal congestion (including fever) and hay fever.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ephedrine hydrochloride - oral tablet - 15mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ephedrine hydrochloride - oral tablet - 30mg

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - felodipine, ramipril - tablet prolonged release - 5/5 milligram - ace inhibitors and calcium channel blockers

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - pseudoephedrine hydrochloride, chlorphenamine maleate, paracetamol - tablet - paracetamol 325 mg pseudoephedrine hydrochloride 15 mg chlorphenamine maleate 1 mg - analgesics

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; dextromethorphan hydrobromide monohydrate, quantity: 15 mg; paracetamol, quantity: 500 mg - tablet, film coated - excipient ingredients: carnauba wax; purified water; povidone; magnesium stearate; hydrogenated vegetable oil; croscarmellose sodium; microcrystalline cellulose; pregelatinised maize starch; sodium starch glycollate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - provides temporary relief of nagging cough and discomfort associated with cold and flu: relieves blocked noses, dries runny noses, provides temporary relief of cough and headache, relieves body aches and pains, reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 49.7 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; brilliant scarlet 4r aluminium lake - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 37.275 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 18.6375 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide yellow; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pc holdings pty limited - phentermine hydrochloride, quantity: 49.7 mg - tablet, modified release - excipient ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; brilliant scarlet 4r aluminium lake - phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (bmi) of 30 kg/m2 or greater.,the treatment with phentermine can be initiated in overweight patients with a lower bmi (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.